×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北... [15]
吉林大学白求恩第一医... [6]
内容类型
期刊论文 [15]
会议论文 [6]
发表日期
2019 [2]
2018 [10]
2017 [6]
2014 [1]
2013 [2]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共21条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
作者升序
作者降序
提交时间升序
提交时间降序
题名升序
题名降序
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
期刊论文
2019, 卷号: 120, 页码: 20-30
作者:
Robson Mark
;
Ruddy Kathryn J
;
Im Seock-Ah
;
Senkus Elżbieta
;
Xu Binghe
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2020/01/03
BRCA
Breast cancer
EORTC QLQ-C30
Health-related quality of life
Olaparib
OlympiAD
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
期刊论文
2019, 卷号: 15, 期号: 21, 页码: 2489-2501
作者:
Iwata Hiroji
;
Masuda Norikazu
;
Kim Sung-Bae
;
Inoue Kenichi
;
Rai Yoshiaki
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2020/01/03
Asia
HER2
early stage breast cancer
efficacy
extended adjuvant therapy
neratinib
safety
tyrosine kinase inhibitor
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Domchek, Susan M.
;
Robson, Mark
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2019/12/05
Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Li, Wei
;
Im, Seock-Ah
;
Xu, Binghe
;
Robson, Mark
;
Ouyang, Quchang
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2019/12/05
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Robson, Mark
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
;
Masuda, Norikazu
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2019/12/05
Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Im, Seock-Ah
;
Xu, Binghe
;
Li, Wei
;
Robson, Mark
;
Ouyang, Quchang
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2019/12/05
Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
会议论文
CANCER RESEARCH, 2018-02-01
作者:
Im, Seock-Ah
;
Xu, Binghe
;
Li, Wei
;
Robson, Mark
;
Ouyang, Quchang
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2020/01/03
Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
期刊论文
2018, 卷号: 78, 期号: 4
作者:
Im, Seock-Ah
;
Xu, Binghe
;
Li, Wei
;
Robson, Mark
;
Ouyang, Quchang
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2020/01/03
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
期刊论文
2018, 卷号: 78, 期号: 4
作者:
Domchek, Susan M.
;
Robson, Mark
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2020/01/03
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
会议论文
CANCER RESEARCH, 2018-02-01
作者:
Domchek, Susan M.
;
Robson, Mark
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2020/01/03
©版权所有 ©2017 CSpace - Powered by
CSpace